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Xinghua Zhen et al.3441. Introduction
Isatin (2,3-dioxindole) is an endogenous compound identiﬁed in
humans and its effect has been studied in a variety of systems.
Biological properties of isatin include a range of actions in the
brain, protection against certain types of bacterial infections,
antiproliferative, anti-inﬂammatory, antiprotozoal, proconvulsive
and anticonvulsive activities1–3.
In addition, Sridhar et al.4 reported the anticonvulsant activity
of hydrazones, the Schiff and Mannich bases of isatin, by the
maximal electroshock method (MES) and metrazol-induced con-
vulsions (MET). Li et al.5 studied the inhibitory effect of isatin on
amygdaloid kindling in rats, seizure-inducing and anticonvulsant
effect in convulsion models. Pajouhesh et al.6 synthesized a series
of cyclohexane and other cyclic ketone derivatives of isatin and
screened them for anticonvulsant activity. These results suggest
that the researchers explored isatin as a new chemical entity with
potential anticonvulsant activity. Furthermore, several researchers
reported that isatin can not only evidently improve internal
monoamine neurotransmitter to antagonize electric7 and
metrazol-induced seizure in mice effectively, but also decrease
the epilepsy probability of audiogenic seizure in rats and enhance
the anticonvulsant effect of propranolol8–10. In addition, in our
studies11, we synthesized a series of isatin-1-N-phenylacetamide
derivatives and tested their anticonvulsant activity. Among these
analogs, the compound I (Fig. 1) showed the highest antic-
onvulsant activity in the anti-MES and anti-PTZ tests.
As a result of our continuous effort in this area, a series of new
2-(5-methyl-2,3-dioxoindolin-1-yl)acetamide derivatives were
synthesized (Scheme 1). The synthesized compounds were cha-
racterized by IR, 1H NMR, 13C NMR and high resolution mass
spectra, and evaluated for their anticonvulsant activity against
convulsions evoked by chemical substance pentylenetetrazole–
Figure 1 The structures of compounds I, 4a–q
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Scheme 1 The synthetic pathway of titled compounds 4a–q Reaction
concentrated H2SO4; (iii) ClCH2COCl, HOAc; (iv) DMF, KI, K2CO3.(PTZ) and antidepressant activity by the forced swimming test
(FST), respectively.2. Results and discussion
The targeted compounds 4a–q were synthesized according to the
sequence shown in Scheme 112. Brieﬂy compound 1 was prepared
by the condensation of p-methlyphenylamine with chloral hydrate
and hydroxylamine hydrochloride in 89% yield. Then, the
subsequent cyclization of compound 1 in the presence of
concentrated sulfuric acid at 80 1C afforded compound 2. Com-
pounds 3a–q were obtained by an acylation reaction of substituted
anilines using 2-chloroacetyl chloride in 80%-92% yields. Finally,
compounds 4a–q were obtained by an alkylation reaction of
compounds 3a–q with compound 2.
The anticonvulsant activity of the synthesized compounds 4a-q
was investigated in PTZ-induced model against convulsions and
the results from these experiments are shown in Table 1. To
explore the structure-activity relationships of 2-(5-methyl-2,3-
dioxoindolin-1-yl)acetamide derivatives, we varied the substituents
on the phenyl group in the phenylacetamide ring, which contained
both electron-withdrawing and electron-donating substituents.
Compounds 4a–q and the reference drug carbamazepine were
administered i.p. into mice at a dose of 100 mg/kg. Among the
synthesized compounds, eleven compounds were found to be
protective against PTZ-induced seizure and showed the anti-
convulsant activity. Analyzing the activity of eleven compounds
(4a, 4d, 4f, 4h, 4k–q) led to the following structure-activity
relationship. The electron-donating groups showed the following
trend in anticonvulsant activity: -2-CH3-C6H44-4-OCH3-C6H44
CH2C6H5Ecompound I, in which the methyl group at the
3-position and 4-position on the phenyl ring did not exhibit the
anticonvulsant activity against PTZ-induced seizures. The
structure-activity relationships of compounds 4e–p were analyzed.
Freqently, the activity is markedly changed upon the introduction
of a halogen atom. Therefore, in this paper some halogen-
substituted derivatives were designed and synthesized. All halo-
genated compounds (4e–p) except 4e, 4g, 4i, and 4j displayed the
anticonvulsant activity against PTZ-induced seizure, The Br
analog showed higher anticonvulsant activity than F and Cl
analogs and the rank of the activity order of halogen-substituted
derivatives was Br4F4Cl. Bis-halogenated compounds 4n (2,4-
Cl2) and 4o (2,4-Br2) also showed the anticonvulsant activity against
PTZ-induced seizure. In addition, compound 4p with an electron-N
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and condition: (i) CCl3CH(OH)2, NH2OH HCl, Na2SO4, HCl; (ii)
Table 1 Effect of compounds 4a–q on PTZ-induced convulsion in mice (test drug administered i.p.).
Compd. Dosage (mg/kg) PTZ Toxicity
Clonic seizures Tonic seizures Lethality 0.5 h 4 h
I 100 1/3 2/3 2/3 0/3 0/3
4a 100 3/3 0/3 0/3 0/3 0/3
4b 100 0/3 3/3 3/3 0/3 0/3
4c 100 0/3 3/3 3/3 0/3 0/3
4d 100 2/3 1/3 1/3 0/3 0/3
4e 100 0/3 3/3 3/3 0/3 0/3
4f 100 3/3 0/3 0/3 0/3 0/3
4g 100 0/3 3/3 3/3 0/3 0/3
4h 100 1/3 2/3 2/3 0/3 0/3
4i 100 0/3 3/3 3/3 0/3 0/3
4j 100 0/3 3/3 3/3 0/3 0/3
4k 100 1/3 2/3 2/3 0/3 0/3
4l 100 1/3 2/3 2/3 0/3 0/3
4m 100 1/3 2/3 2/3 0/3 0/3
4n 100 1/3 2/3 2/3 0/3 0/3
4o 100 1/3 2/3 2/3 0/3 0/3
4p 100 3/3 0/3 0/3 0/3 0/3
4q 100 1/3 2/3 2/3 0/3 0/3
Carbamazepine 100 3/3 3/3 0/3 0/3 0/3
PTZ: subcutaneous pentylenetetrazole (metrazol) seizure test; 0/3: no activity at dose level; 3/3 (clonic seizures): noticeable activity at dose level.
Table 2 Antidepressant activities of the compounds.
Compd. Dose (mg/kg) Antidepressant activitya
I 100 98.5723.3
4a 100 114.876.0
4b 100 101.2718.7
4c 100 76.2718.3
4d 100 92.0719.5
4e 100 110.3722.6
4f 100 98.7716.7
4g 100 113.378.7
4h 100 117.2716.5
4i 100 112.2726.0
4j 100 111.3724.2
4k 100 101.8712.9
4n 100 101.3718.4
4o 100 121.2715.6
Fluoxetine 10 58.579.3nnn
Control – 125.2726.5
aValues represent the mean7SEM (n¼10).
nnnPo0.01, signiﬁcantly compared to control (Turkey's test).
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None of the compounds showed neurotoxicity at the same dose levels.
The FST was designed by Porsolt et al.13 as a primary screening test
for the antidepressant activity and is a behavioral test used to predict the
efﬁcacy of antidepressants. The immobility time observed in the test
reﬂects a state of lowered mood or hopelessness in animals, thus these
models are the most widely used tools for preclinical screening of the
putative anti-depressive agents and have good predictive values for
anti-depressive efﬁcacy in humans14,15. The obtained data on the
antidepressant-like activity of compounds 4a–q and the reference drug
ﬂuoxetine (FLU) are given in Table 2 and Fig. 2 in the FST test. Except
compounds 4l (3-Br), 4m (4-Br), and 4p (3-CF3), none of the halogen
substituted derivatives 4e–p showed potent antidepressant-like activ-
ity. We also investigated the inﬂuence of electron-donating groups
(4a–d and 4q). The results exhibited that compound 4q signiﬁcantly
reduced the duration of the immobility time at 100 mg/kg, compared
with the vehicle control group and were found to have the highest
antidepressant-like activity. The immobility time of mice treated with
compounds 4a–k, 4n, and 4o did not statistically differ from that of
the controls. Acute treatment with compounds 4l, 4m, 4p and 4q
promoted a decrease in the immobility time in the FST, as depicted in
Fig. 2. (control¼125.2726.5; 4l¼65.7717.8; 4m¼78.5719.1;
4p¼75.7718.7; 4q¼88.7718.7; FLU¼58.579.3), and they
reduced the duration of immobility time (47.5%, 37.3%, 29.2% and
39.5%, respectively) compared to the controls. Among them,
compound 4l was found to have the highest antidepressant-like
activity, which is similar to the reference drug FLU (50.96%).
Some compounds that alter motor activity may give false
positive/negative effects in the FST, in particular, psychomotor
stimulants and drugs enhancing motor activity, which decrease
immobility time by stimulating locomotor activity16. Thus, an
additional measurement was carried out with the speciﬁc aim of
observing motor activity. In this study, the effect of compound 4l
on spontaneous locomotor activity was evaluated in the open-ﬁeld
test, a classical animal test used to evaluate the autonomic effects
of drugs and general activity of animals17,18. This study demonstratedthat compound 4l did not signiﬁcantly change motor activity (crossing,
rearing and grooming) in mice (Fig. 3). It is unlikely that the effect of
compound 4l observed in the FST was caused by the stimulation of
general motor activity. This study provides evidence that compound 4l
has an antidepressant-like effect in mice.3. Conclusions
In this study, a series of 2-(5-methyl-2,3-dioxoindolin-1-yl)acet-
amide derivatives were synthesized and evaluated for their
antidepressive and anticonvulsive activities. Eleven synthesized
Figure 2 Immobility time of compounds 4l, 4m, 4p and 4q in mouse
FST. Data expressed as mean7SEM. (n¼10). Statistical analysis of
data was carried out by one-way analysis of variance followed by
Turkey's test. nnPo0.01,nnnPo0.001 vs. Control.
Figure 3 Exploratory activity (counts) in the open-ﬁeld test. The
behavioral parameters were recorded for 3 min. Crossing: number of
line crossings; rearing: number of times seen standing on hind legs;
grooming: number of modiﬁcations; 4l was administered 60 min
before the test. The values represent the mean7SEM (n¼10).
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induced seizure and showed potent anticonvulsive activity. How-
ever, only four compounds (4l, 4m, 4p and 4q) showed the
antidepressant-like activity. Among these compounds, compound
4l showed the highest antidepressant-like activity, and decreased
immobility time by 47.5% at a dose of 100 mg/kg.4. Experimental
Melting points were determined in open capillary tubes and were
uncorrected. IR spectra were recorded (in KBr) on a FT-IR1730
(Bruker, Switzerland), 1H NMR and 13C NMR spectra were
measured on an AV-300 (Bruker, Switzerland), and all chemical
shifts were given in ppm relative to tetramethysilane. High
resolution mass spectra were measured on an MALDI-TOF/TOF
mass spectrometer (Bruker Daltonik, Germany). The majorchemicals were purchased from Aldrich Chemical Corporation.
All other chemicals were of the analytical grade.
4.1. Synthesis of 5-methylindoline-2,3-dione (2)
Concentrated sulfuric acid 20 mL was warmed to 50 1C in a
round-bottomed ﬂask. Compound 1 (0.7 g, 4 mmol) was added to
keep the temperature 50 1C. After the addition of the compound 1
was ﬁnished, the solution was heated to 80 1C for 20 min to
complete the reaction. Then the reaction mixture was cooled to
room temperature and poured to 5 volumes of cracked ice. The
solid was ﬁltered and washed three times with cold water to
remove the sulfuric acid. The crude product was puriﬁed by
recrystallization in EtOH and then dried in the air to provide
compound 219,20. 1H NMR (CDCl3, 300 MHz): δ 10.81 (s, 1H,
-NH), 6.72–7.29 (m, 3H, –C6H3), 2.22 (s, 3H, –CH3).
13C NMR
(CDCl3, 75 MHz): 183.80 (C¼O), 159.47 (C¼O), 148.97 (Ar–
C), 139.06 (Ar–C), 132.43 (Ar–C), 125.12 (Ar–C), 117.90 (Ar–C),
112.42 (Ar–C), 20.46 (CH3–C). MS m/z: 162 [MþH].
4.2. Synthesis of 2-chloro-N-substituted acetamide (3a–q)
Substituted phenylamines or benzylamines (8.8 mmol) were dis-
solved in a mixture of glacial acetic acid (20 mL) and saturated
sodium acetate solution (20 mL). And 2-chloroacetyl chloride
(8.8 mmol) was added dropwise to avoid the vigorous reaction.
The reaction mixture was stirred at 0 1C–5 1C for 1 h, the product
was ﬁltered and washed three times with cold water. The crude
product was puriﬁed by recrystallization in EtOH21.
4.3. Synthesis of 2-(5-methyl-2,3-dioxoindolin-1-yl)acetamide
derivatives (4a–q)
Compound 2 (1.0 g, 6.2 mmol), K2CO3 (0.8 g, 6.2 mmol) and
30 mL DMF were placed in a 100 mL round-bottomed ﬂask. The
mixture was stirred at room temperature for 1 h. The appropriate
compounds 3a–q (6.2 mmol) and KI (0.5 g, 3 mmol) were added
and heated at 80 1C for 1–12 h. The reaction mixture was poured
into water, and then adjusted pH to 3–4 using hydrochloric acid to
obtain precipitation of solid (4a–q). The crude product was
ﬁltered, washed three times with cold water and then dried. The
crude product was puriﬁed by recrystallization in MeOH21. The
physical and spectral data of each compound are given below.
4.3.1. 2-(5-Methyl-2,3-dioxoindolin-1-yl)-N-2-tolylacetamide (4a)
Mp. 233–234 1C; Yield 80%. IR (KBr, cm1): 3321, 1725, 1645,
1248. 1H NMR (CDCl3, 300 MHz): δ 9.57 (s, 1H, -NH), 7.37–
7.81 (m, 3H, C6H3), 6.86–7.40 (m, 4H, C6H4), 4.50 (s, 2H, CH2),
2.30 (s, 3H, CH3), 2.11 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz):
183.38 (C¼O), 166.33 (C¼O), 158.75 (C¼O), 148.37 (Ar–C),
138.80 (Ar–C), 138.53 (Ar–C), 133.37 (Ar–C), 128.49 (Ar–C),
127.48 (Ar–C), 127.19 (Ar–C), 125.00 (Ar–C), 123.27 (Ar–C),
120.47 (Ar–C), 118.02 (Ar–C), 110.50 (Ar–C), 43.50 (CH2–C),
24.84 (CH3–C), 20.72 (CH3–C). ESI-HRMS Calcd. for
C18H16N2O3
þ [MþH]: 309.1161; Found: 309.1174.
4.3.2. 2-(5-Methyl-2,3-dioxoindolin-1-yl)-N-3-tolylacetamide (4b)
Mp. 242–245 1C; Yield 84%. IR (KBr, cm1): 3320, 1726, 1645,
1249. 1H NMR (CDCl3, 300 MHz): δ 9.91 (s, 1H, NH), 7.36–7.91
(m, 3H, C6H3), 6.81–7.64 (m, 4H, C6H4), 4.47 (s, 2H, CH2), 2.28
(s, 3H, CH3), 2.23 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz):
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138.57 (Ar–C), 136.29 (Ar–C), 133.51 (Ar–C), 130.61 (Ar–C),
127.09 (Ar–C), 126.33 (Ar–C), 125.98 (Ar–C), 122.21 (Ar–C),
118.01 (Ar–C), 117.48 (Ar–C), 110.46 (Ar–C), 43.88 (CH2–C),
21.54 (CH3–C), 18.16 (CH3–C). ESI-HRMS Calcd. for
C18H16N2O3
þ [MþH]: 309.1161; Found: 309.1160.
4.3.3. 2-(5-Methyl-2,3-dioxoindolin-1-yl)-N-4-tolylacetamide (4c)
Mp. 258–259 1C; Yield 87%. IR (KBr, cm1): 3324, 1730, 1647,
1246. 1H NMR (CDCl3, 300 MHz): δ 9.79 (s, 1H, NH), 7.33–7.97
(m, 3H, C6H3), 6.78–7.54 (m, 4H, C6H4), 4.46 (s, 2H, CH2), 2.26
(s, 3H, CH3), 2.21 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz):
183.33 (C¼O), 164.76 (C¼O), 158.76 (C¼O), 148.66 (Ar–C),
138.84 (Ar–C), 138.62 (Ar–C), 138.15 (Ar–C), 133.49 (Ar–C),
128.62 (Ar–C), 125.15 (Ar–C), 124.96 (Ar–C), 120.83 (Ar–C),
117.79 (Ar–C), 117.36 (Ar–C), 110.62 (Ar–C), 43.51 (CH2–C),
21.52 (CH3–C), 20.70 (CH3–C). ESI-HRMS Calcd. for
C18H16N2O3
þ [MþH]: 309.1161; Found: 309.1169.
4.3.4. N-(4-Methoxyphenyl)-2-(5-methyl-2,3-dioxoindolin-1-yl)
acetamide (4d)
Mp. 241–243 1C; Yield 79%. IR (KBr, cm1): 3322, 1731, 1646,
1245. 1H NMR (CDCl3, 300 MHz): δ 10.27 (s, 1H, NH), 7.47–
8.14 (m, 3H, C6H3), 6.96–7.52 (m, 4H, C6H4), 4.52 (s, 2H, CH2),
3.34 (s, 3H, OCH3), 2.29 (s, 3H, CH3).
13C NMR (CDCl3,
75 MHz): 183.30 (C¼O), 164.57 (C¼O), 158.80 (C¼O), 148.46
(Ar–C), 138.79 (Ar–C), 134.42 (Ar–C), 133.77 (Ar–C), 133.63
(Ar–C), 129.22 (Ar–C), 125.24 (Ar–C), 124.56 (Ar–C), 122.67
(Ar–C), 120.43 (Ar–C), 117.80 (Ar–C), 110.45 (Ar–C), 69.59
(OCH3–C), 43.53 (CH2–C), 20.71 (CH3–C). ESI-HRMS Calcd.
for C18H16N2O4
þ [MþH]: 325.1110; Found: 325.1119.
4.3.5. N-(2-Fluorophenyl)-2-(5-methyl-2,3-dioxoindolin-1-yl)
acetamide (4e)
Mp. 216–217 1C; Yield 60%. IR (KBr, cm1): 3341, 1731, 1648,
1251. 1H NMR (CDCl3, 300 MHz): δ 10.18 (s, 1H, NH), 7.36–
7.80 (m, 3H, C6H3), 6.89–7.33 (m, 4H, C6H4), 4.49 (s, 2H, CH2),
2.27 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.50 (C¼O),
169.52 (C¼O), 157.86 (C¼O), 144.57 (Ar–C), 138.57 (Ar–C),
136.98 (Ar–C), 134.23 (Ar–C), 133.78 (Ar–C), 130.16 (Ar–C),
127.03 (Ar–C), 125.08 (Ar–C), 123.41 (Ar–C), 120.21 (Ar–C),
117.54 (Ar–C), 116.71 (Ar–C), 43.59 (CH2–C), 20.96 (CH3–C).
ESI-HRMS Calcd. for C17H13FN2O3
þ [MþH]: 313.0910; Found:
313.0917.
4.3.6. N-(3-Fluorophenyl)-2-(5-methyl-2,3-dioxoindolin-1-yl)
acetamide (4f)
Mp. 238–240 1C; Yield 67%. IR (KBr, cm1): 3343, 1732, 1648,
1251. 1H NMR (CDCl3, 300 MHz): δ 10.21 (s, 1H, NH), 7.48–
7.74 (m, 3H, C6H3), 6.78–7.46 (m, 4H, C6H4), 4.50 (s, 2H, CH2),
2.26 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.40 (C¼O),
165.58 (C¼O), 164.20 (C¼O), 158.73 (Ar–C), 148.94 (Ar–C),
140.09 (Ar–C), 138.92 (Ar–C), 136.24 (Ar–C), 133.32 (Ar–C),
130.46 (Ar–C), 117.76 (Ar–C), 115.48 (Ar–C), 110.71 (Ar–C),
107.39 (Ar–C), 43.48 (CH2–C), 20.68 (CH3–C). ESI-HRMS
Calcd. for C17H13FN2O3
þ [MþH]: 313.0910; Found: 313.0915.
4.3.7. N-(4-Fluorophenyl)-2-(5-methyl-2,3-dioxoindolin-1-yl)
acetamide (4g)
Mp. 257–259 1C; Yield 70%. IR (KBr, cm1): 3341, 1731, 1648,
1251. 1H NMR (CDCl3, 300 MHz): δ 10.18 (s, 1H, NH), 7.36–7.80 (m, 3H, C6H3), 6.89–7.33 (m, 4H, C6H4), 4.49 (s, 2H, CH2),
2.27 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.28 (C¼O),
165.12 (C¼O), 158.74 (C¼O), 148.63 (Ar–C), 138.91 (Ar–C),
133.55 (Ar–C), 130.12 (Ar–C), 125.18 (Ar–C), 130.46 (Ar–C),
127.32 (Ar–C), 125.02 (Ar–C), 124.64 (Ar–C), 117.79 (Ar–C),
115.82 (Ar–C), 110.92 (Ar–C), 43.31 (CH2–C), 20.66 (CH3–C).
ESI-HRMS Calcd. for C17H13FN2O3
þ [MþH]: 313.0910; Found:
313.0921.4.3.8. N-(2-Chlorophenyl)-2-(5-methyl-2,3-dioxoindolin-1-yl)
acetamide (4h)
Mp. 198–199 1C; Yield 82%. IR (KBr, cm1): 3334, 1730, 1648,
1251. 1H NMR (CDCl3, 300 MHz): δ 10.23 (s, 1H, NH), 7.37–
7.89 (m, 3H, C6H3), 6.85–7.34 (m, 4H, C6H4), 4.50 (s, 2H, CH2),
2.27 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.33 (C¼O),
164.46 (C¼O), 158.78 (C¼O), 156.25 (Ar–C), 148.51 (Ar–C),
138.79 (Ar–C), 133.57 (Ar–C), 131.16 (Ar–C), 125.18 (Ar–C),
124.78 (Ar–C), 122.02 (Ar–C), 120.79 (Ar–C), 117.82 (Ar–C),
113.85 (Ar–C), 110.51 (Ar–C), 43.46 (CH2–C), 20.70 (CH3–C).
ESI–HRMS Calcd. for C17H13ClN2O3
þ [MþH]: 329.0615; Found:
329.0619.4.3.9. N-(3-Chlorophenyl)-2-(5-methyl-2,3-dioxoindolin-1-yl)
acetamide (4i)
Mp. 251–252 1C; Yield 80%. IR (KBr, cm1): 3330, 1732, 1649,
1250. 1H NMR (CDCl3, 300 MHz): δ 9.83 (s, 1H, NH), 7.43–8.02
(m, 3H, C6H3), 6.93–7.40 (m, 4H, C6H4), 4.59 (s, 2H, CH2), 2.30
(s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.26 (C¼O), 165.21
(C¼O), 158.76 (C¼O), 148.67 (Ar–C), 139.77 (Ar–C), 138.92
(Ar–C), 133.88 (Ar–C), 133.50 (Ar–C), 130.11 (Ar–C), 125.16
(Ar–C), 123.88 (Ar–C), 119.84 (Ar–C), 118.13 (Ar–C), 117.76
(Ar–C), 110.75 (Ar–C), 43.50 (CH2–C), 20.69 (CH3–C). ESI-
HRMS Calcd. for C17H13ClN2O3
þ [MþH]: 329.0615; Found:
329.0620.4.3.10. N-(4-Chlorophenyl)-2-(5-methyl-2,3-dioxoindolin-1-yl)
acetamide (4j)
Mp. 258.5 1C; Yield 87 %. IR (KBr, cm1): 3342, 1734, 1648,
1249. 1H NMR (CDCl3, 300 MHz): δ 10.04 (s, 1H, NH), 7.46–
7.61 (m, 3H, C6H3), 6.77–7.34 (m, 4H, C6H4), 4.47 (s, 2H, CH2),
2.26 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.34 (C¼O),
165.62 (C¼O), 158.72 (C¼O), 148.73 (Ar–C), 138.80 (Ar–C),
134.51 (Ar–C), 133.37 (Ar–C), 129.77 (Ar–C), 127.63 (Ar–C),
125.04 (Ar–C), 123.88 (Ar–C), 119.84 (Ar–C), 118.13 (Ar–C),
117.69 (Ar–C), 110.94 (Ar–C), 43.27 (CH2–C), 20.69 (CH3–C).
ESI-HRMS Calcd. for C17H13ClN2O3
þ [MþH]: 329.0615; Found:
329.0911.4.3.11. N-(2-Bromophenyl)-2-(5-methyl-2,3-dioxoindolin-1-yl)
acetamide (4k)
Mp. 201–202 1C; Yield 81 %. IR (KBr, cm1): 3342, 1733, 1649,
1252. 1H NMR (CDCl3, 300 MHz): δ 9.58 (s, 1H, NH), 7.53–7.63
(m, 3H, C6H3), 6.86–7.49 (m, 4H, C6H4), 4.55 (s, 2H, CH2), 2.28
(s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.21 (C¼O), 165.51
(C¼O), 158.66 (C¼O), 148.22 (Ar–C), 138.67 (Ar–C), 136.27
(Ar–C), 134.22 (Ar–C), 133.51 (Ar–C), 129.23 (Ar–C), 128.52
(Ar–C), 127.07 (Ar–C), 125.00 (Ar–C), 123.88 (Ar–C), 117.46
(Ar–C), 110.94 (Ar–C), 42.86 (CH2–C), 21.06 (CH3–C). ESI-
HRMS Calcd. for C17H13BrN2O3
þ([M þH]þ): 373.0110; Found:
373.0121.
Xinghua Zhen et al.3484.3.12. N-(3-Bromophenyl)-2-(5-methyl-2,3-dioxoindolin-1-yl)
acetamide (4l)
Mp. 240–241 1C; Yield 77 %. IR (KBr, cm1): 3342, 1733, 1649,
1252. 1H NMR (CDCl3, 300 MHz): δ 9.93 (s, 1H, NH), 7.60–7.70
(m, 3H, C6H3), 6.73–7.46 (m, 4H, C6H4), 4.46 (s, 2H, CH2), 2.26
(s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.19 (C¼O), 165.39
(C¼O), 158.72 (C¼O), 148.36 (Ar–C), 138.76 (Ar–C), 135.48
(Ar–C), 133.66 (Ar–C), 132.86 (Ar–C), 128.01 (Ar–C), 127.42
(Ar–C), 126.97 (Ar–C), 125.22 (Ar–C), 118.29 (Ar–C), 117.82
(Ar–C), 110.70 (Ar–C), 43.33 (CH2–C), 20.72 (CH3–C). ESI-
HRMS Calcd. for C17H13BrN2O3
þ [MþH]: 373.0110; Found:
373.0119.
4.3.13. N-(4-Bromophenyl)-2-(5-methyl-2,3-dioxoindolin-1-yl)
acetamide (4m)
Mp. 234–235 1C; Yield 83 %. IR (KBr, cm1): 3340, 1732, 1647,
1250. 1H NMR (CDCl3, 300 MHz): δ 10.00 (s, 1H, NH), 7.55–
8.03 (m, 3H, C6H3), 7.00–7.55 (m, 4H, C6H4), 4.56 (s, 2H, CH2),
2.30 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.14 (C¼O),
165.00 (C¼O), 158.79 (C¼O), 148.23 (Ar–C), 138.81 (Ar–C),
133.81 (Ar–C), 130.13 (Ar–C), 127.08 (Ar–C), 126.14 (Ar–C),
125.39 (Ar–C), 123.06 (Ar–C), 122.15 (Ar–C), 118.37 (Ar–C),
117.81 (Ar–C), 110.30 (Ar–C), 43.58 (CH2–C), 20.69 (CH3–C).
ESI-HRMS Calcd. for C17H13BrN2O3
þ [MþH]: 373.0110; Found:
373.0123.
4.3.14. N-(2,6-Dichlorophenyl)-2-(5-methyl-2,3-dioxoindolin-1-
yl)acetamide (4n)
Mp. 268–270 1C; Yield 73 %. IR (KBr, cm1): 3342, 1730, 1649,
1253. 1H NMR (CDCl3, 300 MHz): δ 10.08 (s, 1H, NH), 7.55–
7.85 (m, 3H, C6H3), 6.85–7.43 (m, 3H, C6H3), 4.52 (s, 2H, CH2),
2.29 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.24 (C¼O),
164.90 (C¼O), 158.75 (C¼O), 148.46 (Ar–C), 138.86 (Ar–C),
136.90 (Ar–C), 133.67 (Ar–C), 130.56 (Ar–C), 128.66 (Ar–C),
127.48 (Ar–C), 125.27 (Ar–C), 121.55 (Ar–C), 120.34 (Ar–C),
117.76 (Ar–C), 110.49 (Ar–C), 43.48 (CH2–C), 20.70 (CH3–C).
ESI-HRMS Calcd. for C17H12Cl2N2O3
þ [MþH]: 363.0225; Found:
363.0229.
4.3.15. N-(2,6-Dibromophenyl)-2-(5-methyl-2,3-dioxoindolin-1-
yl)acetamide (4o)
Mp. 272–274 1C; Yield 70 %. IR (KBr, cm1): 3340, 1736, 1652,
1250. 1H NMR (CDCl3, 300 MHz): δ 10.06 (s, 1H, NH), 7.42–
8.03 (m, 3H, C6H3), 6.93–7.39 (m, 3H, C6H3), 4.60 (s, 2H, CH2),
2.29 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.41 (C¼O),
165.25 (C¼O), 158.81 (C¼O), 148.95 (Ar–C), 138.96 (Ar–C),
137.99 (Ar–C), 133.32 (Ar–C), 131.87 (Ar–C), 128.56 (Ar–C),
127.35 (Ar–C), 125.07 (Ar–C), 121.82 (Ar–C), 117.83 (Ar–C),
116.00 (Ar–C), 111.07 (Ar–C), 43.57 (CH2–C), 20.64 (CH3–C).
ESI-HRMS Calcd. for C17H12Br2N2O3
þ [MþH]: 451.9215; Found:
451.9197.
4.3.16. 2-(5-Methyl-2,3-dioxoindolin-1-yl)-N-(3-
(triﬂuoromethyl)phenyl)acetamide (4p)
Mp. 234–235 1C; Yield 65 %. IR (KBr, cm1): 3341, 1731, 1648,
1251. 1H NMR (CDCl3, 300 MHz): δ 10.12 (s, 1H, NH), 7.52–
7.60 (m, 3H, C6H3), 6.82–7.50 (m, 4H, C6H4), 4.53 (s, 2H, CH2),
2.34 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz): 183.90 (C¼O),
169.50 (C¼O), 165.54 (C¼O), 163.55 (Ar–C), 153.08 (Ar–C),
143.55 (Ar–C), 138.82 (Ar–C), 138.50 (Ar–C), 130.07 (Ar–C),
126.94 (Ar–C), 126.84 (Ar–C), 122.56 (Ar–C), 120.17 (Ar–C),119.18 (Ar–C), 113.13 (Ar–C), 99.00 (Ar–C), 48.25 (CH2–C),
25.44 (CH3–C). ESI-HRMS Calcd. for C18H13F3N2O3
þ [MþH]:
363.0878; Found: 363.0871.
4.3.17. N-Benzyl-2-(5-methyl-2,3-dioxoindolin-1-yl)acetamide (4q)
Mp. 192–194 1C; Yield 75 %. IR (KBr, cm1): 3343, 1733, 1649,
1253. 1H NMR (CDCl3, 300 MHz): δ 8.68 (s, 1H, NH), 7.33–7.89
(m, 3H, C6H3), 6.77–7.25 (m, 5H, C6H5), 4.34 (s, 2H, CH2), 4.29
(s, 2H, CH2), 2.29 (s, 3H, CH3).
13C NMR (CDCl3, 75 MHz):
183.19 (C¼O), 169.56 (C¼O), 165.30 (C¼O), 163.34 (Ar–C),
158.77 (Ar–C), 148.37 (Ar–C), 141.41 (Ar–C), 138.87 (Ar–C),
133.79 (Ar–C), 125.91 (Ar–C), 125.37 (Ar–C), 119.87 (Ar–C),
117.74 (Ar–C), 110.42 (Ar–C), 86.59 (Ar–C), 51.43 (Ar-CH2),
43.54 (CH2–C), 20.67 (CH3–C). ESI-HRMS Calcd. for
C18H16N2O3
þ: 309.1161; Found: 309.1176.
4.4. PTZ-induced seizure
PTZ-induced seizure test was carried out by the standard proce-
dures described in the Antiepileptic Drug Development Program
of the National Institutes of Health (USA)22,23. All compounds,
which were dissolved in DMSO, were evaluated for the anti-
convulsive activity in BALB/e mice in the 18–25 g weight range.
At 30 min after the administration of the test compounds, 85 mg/kg
of PTZ dissolved in saline was administered intraperitoneally (i.p.).
The animals were placed in individual cages and observed for 1 h.
The number of clonic, tonic seizures, and lethality as well as the
number of deaths was noted.
4.5. Forced swimming test (FST)
The FST used was described in detail elsewhere by Porsolt et al.24,25.
The synthesized compounds were screened for their anti-depressive
activity. Local breed, male BALB/e mice (18–25 g) were used in the
FST under standard conditions with free access to food and water.
They were housed in groups of six. On the testing day, mice were
dropped one at a time into a plexiglass cylinder (height 25 cm,
diameter 10 cm) containing 10 cm of water at 2272 1C. During the
testing, mice were assigned into different groups (n¼8 for each
group). The synthesized compounds (100 mg/kg) and ﬂuoxetine as a
reference antidepressant (10 mg/kg) were dissolved in DMSO and
injected intraperitoneally (i.p.) in a standard volume of 0.1 mL/20 g
body weight, 30 min prior to the test. Then, the mice were dropped
individually into the pelxiglass cylinder and left in the water for
6 min. After the ﬁrst 2 min of the initial vigorous struggling, the
animals were immobile. A mouse was judged immobile if it ﬂoated in
the water in an upright position and made only slight movements in
order to prevent sinking. The duration of immobility was recorded
during the last 4 min of the 6-min-test. Immobility period was
regarded as the time spent by the mouse ﬂoating in the water without
struggling and making only those movements necessary to keep its
head above the water. Following swimming sessions, they were then
towel dried and returned to their housing condition. The animals were
used only once in this test. All FSTs were performed between 11:00
and 17:00.
4.6. Rotarod test
At 30 min after the administration of the compounds, the animals
were tested on a 1-in. diameter, knurled plastic rod rotating at
Synthesis and activity of 2,3-dioxoindolin acetamide derivatives 3496 rpm for 1 min. Neurotoxicity was indicated by the inability of an
animal to maintain equilibrium in each of three trials26.
4.7. Open-ﬁeld test
Open-ﬁeld tests were used to evaluate the exploratory activity of
the animals27. The investigated compound 4l suspended in
aqueous Tween 80 was administered 60 min before the experi-
ment. The study was carried out in mice according to the Archer's
method28, with slight modiﬁcations. Each mouse was placed
individually in the center of an open-ﬁeld apparatus, and the
locomotor activity was assessed. The open-ﬁeld apparatus was a
non-transparent plastic container (80 cm 60 cm 30 cm), with
the underside divided into 48 units of size 10 cm 10 cm, without
walls. The animals were gently placed in the center of the platform
and were allowed to explore their surroundings. Hand-operated
counters were used to score locomotion (ambulation, numbers of
crossing lines with all four paws) and rearing frequencies (number
of times an animal stood on its hind legs) for 3 min. The
researchers, who did not know which groups had been treated,
scored the behaviors in the open-ﬁeld. The experiments were
performed in a dark room, and the apparatus was illuminated by a
60-W bulb giving a yellowish light, positioned 1 m above the
center of the apparatus.
4.8. Statistical analysis
Results are expressed as mean7SEM; n represents the number of
animals. Data obtained from pharmacological experiments were
analyzed with Turkey's multiple comparison tests, using the
GraphPad Prism program (GraphPad Software Inc., San Diego,
USA). P value of less than 0.05 was considered statistically
signiﬁcant.
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